The economics of virus-like particle and capsomere vaccines

Biochemical Engineering Journal

Volumn 90, Issue , 2014, Pages 255-263

  Chuan, Yap P ^a   Wibowo, Nani ^a   Lua, Linda H L ^a   Middelberg, Anton P J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Bioprocess design; Biosynthesis; Microbial growth; Process integration; Vaccine; Virus like particleX

Indexed keywords

ANTIGENS; BIOCHEMISTRY; BIOSYNTHESIS; ECONOMIC ANALYSIS; FERMENTERS; MANUFACTURE; MONTE CARLO METHODS; PROBABILITY DISTRIBUTIONS; TECHNOLOGY; VIRUSES;

BIOMASS CONCENTRATIONS; BIOPROCESS DESIGN; MICROBIAL GROWTH; PROCESS INTEGRATION; UNIT PRODUCTION COST; VACCINE DISTRIBUTIONS; VIRUS-LIKE PARTICLES; VIRUS-LIKE PARTICLEX;

VACCINES;

VIRUS VACCINE;

ARTICLE; BIOMASS; BIOREACTOR; CAPSOMERE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAFILTRATION; DILUTION; DRUG MANUFACTURE; ECONOMIC EVALUATION; EVALUATION STUDY; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; PROCESS DESIGN; PROCESS MODEL; PRODUCTIVITY; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; STOCHASTIC MODEL; VACCINE PRODUCTION; VIRUS CAPSID; VIRUS LIKE AGENT;

EID: 84903839299     PISSN: 1369703X     EISSN: 1873295X     Source Type: Journal    
DOI: 10.1016/j.bej.2014.06.005     Document Type: Article

References (35)

1. WHO The Global Burden of Disease, 2004 Update 2008.
2. Henderson D.A., Fenner F. Recent events and observations pertaining to smallpox virus destruction in 2002. Clin. Infect. Dis. 2001, 33:1057-1059.
3. Heinsbroek E., Ruitenberg E.J. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 2010, 28:3778-3783.
4. Moss W.J., Griffin D.E. Global measles elimination. Nat. Rev. Microbiol. 2006, 4:900-908.
5. Lee L.A., Franzel L., Atwell J., Datta S.D., Friberg I.K., Goldie S.J., Reef S.E., Schwalbe N., Simons E., Strebel P.M., Sweet S., Suraratdecha C., Tam Y., Vynnycky E., Walker N., Walker D.G., Hansen P.M. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance. Vaccine 2013, 31(Suppl. 2):B61-B72.
6. Middelberg A.P.J., Rivera-Hernandez T., Wibowo N., Lua L.H.L., Fan Y.Y., Magor G., Chang C., Chuan Y.P., Good M.F., Batzloff M.R. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 2011, 29:7154-7162.
7. L. Lua, A. Middelberg, VLP based vaccine delivery system, WIPO Patent WO/2008/040060 (2008).
8. L. Lua, A. Middelberg, Immunogenic compositions and methods therefor, WIPO Patent Application WO/2013/020183 (2013).
9. Wibowo N., Chuan Y.P., Lua L.H.L., Middelberg A.P.J. Modular engineering of a microbially-produced viral capsomere vaccine for influenza. Chem. Eng. Sci. 2012, 103:12-20.
10. Chuan Y.P., Rivera-Hernandez T., Wibowo N., Connors N.K., Wu Y., Hughes F.K., Lua L.H., Middelberg A.P. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine. Biotechnol. Bioeng. 2013, 110:2343-2351.
11. Rivera-Hernandez T., Hartas J., Wu Y., Chuan Y.P., Lua L.H., Good M., Batzloff M.R., Middelberg A.P. Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). Vaccine 2013, 31:1950-1955.
12. Liew M.W., Rajendran A., Middelberg A.P. Microbial production of virus-like particle vaccine protein at gram-per-litre levels. J. Biotechnol. 2010, 150:224-231.
13. Chuan Y.P., Lua L.H.L., Middelberg A.P.J. High-level expression of soluble viral structural protein in Escherichia coli. J. Biotechnol. 2008, 134:64-71.
14. Stehle T., Harrison S.C. High-resolution structure of a polyomavirus VP1-oligosaccharide complex: implications for assembly and receptor binding. EMBO J. 1997, 16:5139-5148.
15. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003, 11:438-444.
16. Pattenden L.K., Middelberg A.P.J., Niebert M., Lipin D.I. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol. 2005, 23:523-529.
17. Lipin D.I., Raj A., Lua L.H.L., Middelberg A.P.J. Affinity purification of viral protein having heterogeneous quaternary structure: modeling the impact of soluble aggregates on chromatographic performance. J. Chromatogr. A 2009, 1216:5696-5708.
18. 2+-triggered switch in the thermodynamic attraction between structural protein capsomeres. J. R. Soc. Interface 2010, 7:409-421.
19. Liew M.W.O., Chuan Y.P., Middelberg A.P.J. High-yield and scalable cell-free assembly of virus-like particles by dilution. Biochem. Eng. J. 2012, 67:88-96.
20. Liew M.W.O., Chuan Y.P., Middelberg A.P.J. Reactive diafiltration for assembly and formulation of virus-like particles. Biochem. Eng. J. 2012, 68:120-128.
21. Sambrook J., Russell D.W. Molecular Cloning: A Laboratory Manual 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 3rd ed.
22. Lee G.H., Cooney D., Middelberg A.P., Choe W.S. The economics of inclusion body processing. Bioprocess Biosyst. Eng. 2006, 29:73-90.
23. Cook J.C., Joyce J.G., George H.A., Schultz L.D., Hurni W.M., Jansen K.U., Hepler R.W., Ip C., Lowe R.S., Keller P.M., Lehman E.D. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expr. Purif. 1999, 17:477-484.
24. Grushka E., Grinberg N. Advances in Chromatography 2009, CRC Press, Boca Raton, Florida.
25. Liu H.F., McCooey B., Duarte T., Myers D.E., Hudson T., Amanullah A., van Reis R., Kelley B.D. Exploration of overloaded cation exchange chromatography for monoclonal antibody purification. J. Chromatogr. A 2011, 1218:6943-6952.
26. Ding Y., Chuan Y.P., He L.Z., Middelberg A.P.J. Modeling the competition between aggregation and self-assembly during virus-like particle processing. Biotechnol. Bioeng. 2010, 107:550-560.
27. Middelberg A., Fan Y. A Method of Preparation of a Biological Particulate Structure 2012.
28. Biwer A., Griffith S., Cooney C. Uncertainty analysis of penicillin V production using Monte Carlo simulation. Biotechnol. Bioeng. 2005, 90:167-179.
29. Zhuang J., Marchant M.A., Nokes S.E., Strobel H.J. Economic analysis of cellulase production methods for bio-ethanol. Appl. Eng. Agric. 2007, 23:679-687.
30. Tripathi N.K., Sathyaseelan K., Jana A.M., Rao P.V.L. High yield production of heterologous proteins with Escherichia coli. Def. Sci. J. 2009, 59:137-146.
31. Gandhi G., Lydon P., Cornejo S., Brenzel L., Wrobel S., Chang H. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020. Vaccine 2013, 31(Suppl. 2):B137-B148.
32. Kane M.A. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine. Gynecol. Oncol. 2010, 117:S32-S35.
33. Dawood F.S., Iuliano A.D., Reed C., Meltzer M.I., Shay D.K., Cheng P.Y., Bandaranayake D., Breiman R.F., Brooks W.A., Buchy P., Feikin D.R., Fowler K.B., Gordon A., Hien N.T., Horby P., Huang Q.S., Katz M.A., Krishnan A., Lal R., Montgomery J.M., Mølbak K., Pebody R., Presanis A.M., Razuri H., Steens A., Tinoco Y.O., Wallinga J., Yu H., Vong S., Bresee J., Widdowson M.A. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect. Dis. 2012, 12:687-695.
34. Barrett P.N., Portsmouth D., Ehrlich H.J. Developing cell culture-derived pandemic vaccines. Curr. Opin. Mol. Ther. 2010, 12:21-30.
35. Almond J.W. Vaccine renaissance. Nat. Rev. Microbiol. 2007, 5:478-481.